Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

ALINA ALINA: Active Learning Inference for Nucleic Acid Delivery

Coordinator
Ludwig-Maximilians-Universitaet Muenchen, Germany
Runs
1 January 2027 to 30 June 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101334799

What the project is doing

In the project's own words, from its summary on CORDIS.

RNA therapeutics hold enormous potential, yet progress is hindered by slow, costly, and empirical formulation workflows that translate poorly from in vitro to in vivo and complicate freedom-to-operate (FTO) decisions. Current strategies rely on trial-and-error, one-factor-at-a-time approaches that deliver incremental gains and rarely unlock extrahepatic delivery. ALINA will establish the technical and commercial proof-of-concept for an integrated machine learning (ML) and molecular dynamics (MD) platform that accelerates the design and optimization of mRNA-loaded lipid nanoparticle (LNP) formulations.

The platform combines curated multi-modal datasets, physics-informed MD descriptors, active-learning experiment selection, and higher-translational biological models to identify globally optimal, FTO-conscious LNP compositions with significantly fewer experiments. The project will deliver (i) an industry-compatible MVP of the ALINA platform, (ii) quantitative benchmarks demonstrating faster convergence and improved predictive accuracy versus current methods, and (iii) an IP strategy covering newly identified lipid components and a commercialization plan combining platform-access services and licensing.

By improving development speed, predictive power, resource efficiency, and route-to-impact beyond the liver, ALINA addresses a major bottleneck in RNA therapeutics development and supports the broader adoption of data-driven formulation across biotech and pharma that could benefit at least 2-4 million patients annually.

Topics

Who is involved

OrganisationCityCountryRole
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI